|
1
|
Karimi P, Islami F, Anandasabapathy S,
Freedman ND and Kamangar F: Gastric cancer: Descriptive
epidemiology, risk factors, screening, and prevention. Cancer
Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guggenheim DE and Shah MA: Gastric cancer
epidemiology and risk factors. J Surg Oncol. 107:230–236. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crew KD and Neugut AI: Epidemiology of
gastric cancer. World J Gastroenterol. 12:354–362. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patru CL, Surlin V, Georgescu I and Patru
E: Current issues in gastric cancer epidemiology. Rev Med Chir Soc
Med Nat Iasi. 117:199–204. 2013.PubMed/NCBI
|
|
5
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI
|
|
6
|
Qiu MZ, Cai MY, Zhang DS, Wang ZQ, Wang
DS, Li YH and Xu RH: Clinicopathological characteristics and
prognostic analysis of Lauren classification in gastric
adenocarcinoma in China. J Transl Med. 11:582013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zheng H, Takahashi H, Murai Y, Cui Z,
Nomoto K, Miwa S, Tsuneyama K and Takano Y: Pathobiological
characteristics of intestinal and diffuse-type gastric carcinoma in
Japan: An immunostaining study on the tissue microarray. J Clin
Pathol. 60:273–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen YC, Fang WL, Wang RF, Liu CA, Yang
MH, Lo SS, Wu CW, Li AF, Shyr YM and Huang KH: Clinicopathological
variation of lauren classification in gastric cancer. Pathol Oncol
Res. 22:197–202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hommel C, Knoedler M, Bojarski C, Schumann
M, Epple HJ, Zeitz M and Daum S: Diffuse gastric cancer with
peritoneal carcinomatosis can mimic Crohn's disease. Case Rep
Gastroenterol. 6:695–703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stiekema J, Cats A, Kuijpers A, van
Coevorden F, Boot H, Jansen EP, Verheij M, Ponz Balague O,
Hauptmann M and van Sandick JW: Surgical treatment results of
intestinal and diffuse type gastric cancer. Implications for a
differentiated therapeutic approach? Eur J Surg Oncol. 39:686–693.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kaneko S and Yoshimura T: Time trend
analysis of gastric cancer incidence in Japan by histological
types, 1975–1989. Br J Cancer. 84:400–405. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamamoto E, Suzuki H, Takamaru H, Yamamoto
H, Toyota M and Shinomura Y: Role of DNA methylation in the
development of diffuse-type gastric cancer. Digestion. 83:241–249.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu DG: Epigenetic alterations in gastric
cancer. Mol Med Rep. 12:3223–3230. 2015.(Review). PubMed/NCBI
|
|
14
|
Martínez-Madrigal F, Ortiz-Hidalgo C,
Torres-Vega C, Alvarez L, Manzo-Montaño A, García-López L and
Esquivel-Ayanegui F: Atypical regenerative changes, dysplasia, and
carcinoma in situ in chronic gastritis associated with
Helicobacter pylori. Rev Gastroenterol Mex. 65:11–17.
2000.(In Spanish). PubMed/NCBI
|
|
15
|
Kodama M, Murakami K, Okimoto T, Abe T,
Nakagawa Y, Mizukami K, Uchida M, Inoue K and Fujioka T:
Helicobacter pylori eradication improves gastric atrophy and
intestinal metaplasia in long-term observation. Digestion.
85:126–130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Asaka M: Elimination of gastric cancer
from Japan. Nihon Rinsho. 70:1667–1672. 2012.(In Japanese).
PubMed/NCBI
|
|
17
|
Take S, Mizuno M, Ishiki K, Yoshida T,
Ohara N, Yokota K, Oguma K, Okada H and Yamamoto K: The long-term
risk of gastric cancer after the successful eradication of
Helicobacter pylori. J Gastroenterol. 46:318–324. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vannella L, Lahner E and Annibale B: Risk
for gastric neoplasias in patients with chronic atrophic gastritis:
A critical reappraisal. World J Gastroenterol. 18:1279–1285. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rokkas T, Pistiolas D, Sechopoulos P,
Robotis I and Margantinis G: The long-term impact of
Helicobacter pylori eradication on gastric histology: A
systematic review and meta-analysis. Helicobacter. 12(Suppl 2):
S32–S38. 2007. View Article : Google Scholar
|
|
20
|
Maehata Y, Nakamura S, Fujisawa K, Esaki
M, Moriyama T, Asano K, Fuyuno Y, Yamaguchi K, Egashira I, Kim H,
et al: Long-term effect of Helicobacter pylori eradication
on the development of metachronous gastric cancer after endoscopic
resection of early gastric cancer. Gastrointest Endosc. 75:39–46.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pereyra L, Gómez EJ, Mella JM, Casas G,
Bugari G, Cimmino D, Pedreira S and Boerr LA: Diffuse gastric
cancer associated with Ménétrier's disease. Acta Gastroenterol
Latinoam. 41:142–145. 2011.(In Spanish). PubMed/NCBI
|
|
22
|
Palestro G, Pellicano R, Fronda GR,
Valente G, De Giuli M, Soldati T, Pugliese A, Taraglio S, Garino M,
Campra D, et al: Prevalence of Helicobacter pylori infection
and intestinal metaplasia in subjects who had undergone surgery for
gastric adenocarcinoma in Northwest Italy. World J Gastroenterol.
11:7131–7135. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nardone G, Rocco A and Malfertheiner P:
Review article: Helicobacter pylori and molecular events in
precancerous gastric lesions. Aliment Pharmacol Ther. 20:261–270.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoshida T, Kato J, Maekita T, Yamashita S,
Enomoto S, Ando T, Niwa T, Deguchi H, Ueda K, Inoue I, et al:
Altered mucosal DNA methylation in parallel with highly active
Helicobacter pylori-related gastritis. Gastric Cancer.
16:488–497. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Corso G, Marrelli D and Roviello F:
Familial gastric cancer: Update for practice management. Fam
Cancer. 10:391–396. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oliveira C, Pinheiro H, Figueiredo J,
Seruca R and Carneiro F: Familial gastric cancer: Genetic
susceptibility, pathology, and implications for management. Lancet
Oncol. 16:e60–e70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vogelaar IP, van der Post RS, Bisseling
TM, van Krieken JH, Ligtenberg MJ and Hoogerbrugge N: Familial
gastric cancer: Detection of a hereditary cause helps to understand
its etiology. Hered Cancer Clin Pract. 10:182012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carneiro F: Hereditary gastric cancer.
Pathologe. 33(Suppl 2): S231–S234. 2012. View Article : Google Scholar
|
|
29
|
Machado JC, Oliveira C, Carvalho R, Soares
P, Berx G, Caldas C, Seruca R, Carneiro F and Sobrinho-Simöes M:
E-cadherin gene (CDH1) promoter methylation as the second hit in
sporadic diffuse gastric carcinoma. Oncogene. 20:1525–1528. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim IJ, Kang HC, Shin Y, Park HW, Jang SG,
Han SY, Lim SK, Lee MR, Chang HJ, Ku JL, et al: A TP53-truncating
germline mutation (E287X) in a family with characteristics of both
hereditary diffuse gastric cancer and Li-Fraumeni syndrome. J Hum
Genet. 49:591–595. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim S, Chung JW, Jeong TD, Park YS, Lee
JH, Ahn JY, Kim DH, Choi KD, Lee W, Song HJ, et al: Searching for
E-cadherin gene mutations in early onset diffuse gastric cancer and
hereditary diffuse gastric cancer in Korean patients. Fam Cancer.
12:503–507. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bacani JT, Soares M, Zwingerman R, di
Nicola N, Senz J, Riddell R, Huntsman DG and Gallinger S:
CDH1/E-cadherin germline mutations in early-onset gastric cancer. J
Med Genet. 43:867–872. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Corso G, Pedrazzani C, Pinheiro H,
Fernandes E, Marrelli D, Rinnovati A, Pascale V, Seruca R, Oliveira
C and Roviello F: E-cadherin genetic screening and
clinico-pathologic characteristics of early onset gastric cancer.
Eur J Cancer. 47:631–639. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Humar B, Graziano F, Cascinu S, Catalano
V, Ruzzo AM, Magnani M, Toro T, Burchill T, Futschik ME, Merriman T
and Guilford P: Association of CDH1 haplotypes with susceptibility
to sporadic diffuse gastric cancer. Oncogene. 21:8192–8195. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu YC, Shen CY, Wu HS, Hsieh TY, Chan DC,
Chen CJ, Yu JC, Yu CP, Harn HJ, Chen PJ, et al: Mechanisms
inactivating the gene for E-cadherin in sporadic gastric
carcinomas. World J Gastroenterol. 12:2168–2173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ramos-de la Medina A, More H,
Medina-Franco H, Humar B, Gamboa A, Ortiz LJ, Donohue JH and
Guilford P: Single nucleotide polymorphisms (SNPs) at CDH1 promoter
region in familial gastric cancer. Rev Esp Enferm Dig. 98:36–41.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hoogerbrugge N, Ligtenberg MJ, Nagengast
FM, Bonenkamp JJ and van Krieken JH: Preventive resection of
hereditary diffuse gastric cancer. Ned Tijdschr Geneeskd.
150:2417–2420. 2006.(In Dutch). PubMed/NCBI
|
|
38
|
Kluijt I, Sijmons RH, Hoogerbrugge N,
Vasen HF and Cats A: Familial gastric cancer: Diagnosis, treatment
and periodic surveillance. Ned Tijdschr Geneeskd. 155:A27312011.(In
Dutch). PubMed/NCBI
|
|
39
|
Schildberg CW, Abba M, Merkel S, Agaimy A,
Dimmler A, Schlabrakowski A, Croner R, Leupold JH, Hohenberger W
and Allgayer H: Gastric cancer patients less than 50 years of age
exhibit significant downregulation of E-cadherin and CDX2 compared
to older reference populations. Adv Med Sci. 59:142–146. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim H, An JY, Noh SH, Shin SK, Lee YC and
Kim H: High microsatellite instability predicts good prognosis in
intestinal-type gastric cancers. J Gastroenterol Hepatol.
26:585–592. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Qiu M, Zhou Y, Zhang X, Wang Z, Wang F,
Shao J, Lu J, Jin Y, Wei X, Zhang D, et al: Lauren classification
combined with HER2 status is a better prognostic factor in Chinese
gastric cancer patients. BMC Cancer. 14:8232014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu ZY, Zhan WH, Li JH, He YL, Wang JP, Lan
P, Peng JS and Cai SR: Expression of E-cadherin in gastric
carcinoma and its correlation with lymph node micrometastasis.
World J Gastroenterol. 11:3139–3143. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lazăr D, Tăban S, Ardeleanu C, Dema A,
Sporea I, Cornianu M, Lazăr E and Vernic C: The immunohistochemical
expression of E-cadherin in gastric cancer; correlations with
clinicopathological factors and patients' survival. Rom J Morphol
Embryol. 49:459–467. 2008.PubMed/NCBI
|
|
44
|
Stănculescu D, Mărgăritescu C, Stepan A
and Mitruţ AO: E-cadherin in gastric carcinomas related to
histological prognostic parameters. Rom J Morphol Embryol. 52(Suppl
3): S1107–S1112. 2011.
|
|
45
|
Karayiannakis AJ, Syrigos KN, Chatzigianni
E, Papanikolaou S and Karatzas G: E-cadherin expression as a
differentiation marker in gastric cancer. Hepatogastroenterology.
45:2437–2442. 1998.PubMed/NCBI
|
|
46
|
Asano N, Imatani A, Watanabe T, Fushiya J,
Kondo Y, Jin X, Ara N, Uno K, Iijima K, Koike T, et al: Cdx2
expression and intestinal metaplasia induced by H. pylori
infection of gastric cells is regulated by NOD1-mediated innate
immune responses. Cancer Res. Jan 12–2016.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Almeida R, Almeida J, Shoshkes M, Mendes
N, Mesquita P, Silva E, Van Seuningen I, Reis CA, Santos-Silva F
and David L: OCT-1 is over-expressed in intestinal metaplasia and
intestinal gastric carcinomas and binds to, but does not
transactivate, CDX2 in gastric cells. J Pathol. 207:396–401. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mesquita P, Jonckheere N, Almeida R,
Ducourouble MP, Serpa J, Silva E, Pigny P, Silva FS, Reis C,
Silberg D, et al: Human MUC2 mucin gene is transcriptionally
regulated by Cdx homeodomain proteins in gastrointestinal carcinoma
cell lines. J Biol Chem. 278:51549–51556. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim HS, Lee JS, Freund JN, Min KW, Lee JS,
Kim W, Juhng SW and Park CS: CDX-2 homeobox gene expression in
human gastric carcinoma and precursor lesions. J Gastroenterol
Hepatol. 21:438–442. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Seno H, Oshima M, Taniguchi MA, Usami K,
Ishikawa TO, Chiba T and Taketo MM: CDX2 expression in the stomach
with intestinal metaplasia and intestinal-type cancer: Prognostic
implications. Int J Oncol. 21:769–774. 2002.PubMed/NCBI
|
|
51
|
Mizoshita T, Tsukamoto T, Nakanishi H,
Inada K, Ogasawara N, Joh T, Itoh M, Yamamura Y and Tatematsu M:
Expression of Cdx2 and the phenotype of advanced gastric cancers:
Relationship with prognosis. J Cancer Res Clin Oncol. 129:727–734.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fan Z, Li J, Dong B and Huang X:
Expression of Cdx2 and hepatocyte antigen in gastric carcinoma:
Correlation with histologic type and implications for prognosis.
Clin Cancer Res. 11:6162–6170. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fang WL, Chang SC, Lan YT, Huang KH, Chen
JH, Lo SS, Hsieh MC, Li AF, Wu CW and Chiou SH: Microsatellite
instability is associated with a better prognosis for gastric
cancer patients after curative surgery. World J Surg. 36:2131–2138.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kim JY, Shin NR, Kim A, Lee HJ, Park WY,
Kim JY, Lee CH, Huh GY and Park DY: Microsatellite instability
status in gastric cancer: A reappraisal of its clinical
significance and relationship with mucin phenotypes. Korean J
Pathol. 47:28–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yuan DD, Zhu ZX, Zhang X and Liu J:
Targeted therapy for gastric cancer: Current status and future
directions. Oncol Rep. 35:1245–1254. 2016.(Review). PubMed/NCBI
|
|
56
|
Park DI, Yun JW, Park JH, Oh SJ, Kim HJ,
Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, et al: HER-2/neu
amplification is an independent prognostic factor in gastric
cancer. Dig Dis Sci. 51:1371–1379. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Janjigian YY, Werner D, Pauligk C,
Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E,
Tafe LJ, Tang LH, et al: Prognosis of metastatic gastric and
gastroesophageal junction cancer by HER2 status: A European and USA
International collaborative analysis. Ann Oncol. 23:2656–2662.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sornmayura P, Rerkamnuaychoke B, Jinawath
A and Euanorasetr C: Human epidermal growth-factor receptor 2
overexpression in gastric carcinoma in Thai patients. J Med Assoc
Thai. 95:88–95. 2012.PubMed/NCBI
|
|
59
|
Ishida M, Kagawa S, Shimoyama K, Takehara
K, Noma K, Tanabe S, Shirakawa Y, Tazawa H, Kobayashi H and
Fujiwara T: Trastuzumab-based photoimmunotherapy integrated with
viral HER2 transduction inhibits peritoneally disseminated
HER2-negative cancer. Mol Cancer Ther. Feb 1–2016.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gagliato DM, Jardim DL, Marchesi MS and
Hortobagyi GN: Mechanisms of resistance and sensitivity to
anti-HER2 therapies in HER2+ breast cancer. Oncotarget.
2016.PubMed/NCBI
|
|
61
|
Liu W, Zhong S, Chen J and Yu Y: HER-2/neu
overexpression is an independent prognostic factor for
intestinal-type and early-stage gastric cancer patients. J Clin
Gastroenterol. 46:e31–e37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wu HM, Liu YH, Lin F, Xu FP, Luo DL, Zhang
F, Zhuang HG, Luo XL, Wu WL and Lin XT: Association of HER2 protein
expression with clinicopathologic features and prognosis in Chinese
patients with gastric carcinoma. Zhonghua Bing Li Xue Za Zhi.
40:296–299. 2011.(In Chinese). PubMed/NCBI
|
|
63
|
Förster S, Gretschel S, Jöns T, Yashiro M
and Kemmner W: THBS4, a novel stromal molecule of diffuse-type
gastric adenocarcinomas, identified by transcriptome-wide
expression profiling. Mod Pathol. 24:1390–1403. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kim MA, Lee HS, Yang HK and Kim WH:
Clinicopathologic and protein expression differences between cardia
carcinoma and noncardia carcinoma of the stomach. Cancer.
103:1439–1446. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhao W, Zhu H, Zhang S, Yong H, Wang W,
Zhou Y, Wang B, Wen J, Qiu Z, Ding G, et al: Trop2 is overexpressed
in gastric cancer and predicts poor prognosis. Oncotarget. Dec
22–2015.(Epub ahead of print).
|
|
66
|
He HY, Wang XF, Shen ZB, Chen WD and Sun
YH: Association of transcriptional repressor Snail with Lauren
classification of gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi.
15:852–854. 2012.(In Chinese). PubMed/NCBI
|
|
67
|
Jackson C, Mochlinski K and Cunningham D:
Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs
postoperative chemoradiotherapy. Oncology (Williston Park).
21:1084–1087, 1090, 1096–1098, 1101. 2007.PubMed/NCBI
|
|
68
|
Park SR, Kong SY, Nam BH, Choi IJ, Kim CG,
Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, et al: CYP2A6 and ERCC1
polymorphisms correlate with efficacy of S-1 plus cisplatin in
metastatic gastric cancer patients. Br J Cancer. 104:1126–1134.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wang Z, Chen JQ, Liu JL, Qin XG and Huang
Y: Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical
outcomes of gastric cancer patients treated with
platinum/5-Fu-based chemotherapy: A systematic review. BMC
Gastroenterol. 12:1372012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Takahari D, Boku N, Mizusawa J, Takashima
A, Yamada Y, Yoshino T, Yamazaki K, Koizumi W, Fukase K, Yamaguchi
K, et al: Determination of prognostic factors in Japanese patients
with advanced gastric cancer using the data from a randomized
controlled trial, Japan clinical oncology group 9912. Oncologist.
19:358–366. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ajani JA, Rodriguez W, Bodoky G,
Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A,
Lang I and Falcon S: Multicenter phase III comparison of
cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced
gastric or gastroesophageal adenocarcinoma study: The FLAGS trial.
J Clin Oncol. 28:1547–1553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Narahara H, Iishi H, Imamura H, Tsuburaya
A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C and Sakata Y:
Randomized phase III study comparing the efficacy and safety of
irinotecan plus S-1 with S-1 alone as first-line treatment for
advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer.
14:72–80. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Boku N, Yamamoto S, Fukuda H, Shirao K,
Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, et
al: Gastrointestinal Oncology Study Group of the Japan Clinical
Oncology Group: Fluorouracil versus combination of irinotecan
plus cisplatin versus S-1 in metastatic gastric cancer: A
randomised phase 3 study. Lancet Oncol. 10:1063–1069. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Yamaguchi K, Tada M, Horikoshi N, Otani T,
Takiuchi H, Saitoh S, Kanamaru R, Kasai Y, Koizumi W, Sakata Y and
Taguchi T: Paclitaxel Gastric Cancer Study Group in Japan: Phase II
study of paclitaxel with 3-h infusion in patients with advanced
gastric cancer. Gastric Cancer. 5:90–95. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kato K, Chin K, Yoshikawa T, Yamaguchi K,
Tsuji Y, Esaki T, Sakai K, Kimura M, Hamaguchi T, Shimada Y, et al:
Phase II study of NK105, a paclitaxel-incorporating micellar
nanoparticle, for previously treated advanced or recurrent gastric
cancer. Invest New Drugs. 30:1621–1627. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Koizumi W, Kim YH, Fujii M, Kim HK,
Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, et al: JACCRO
and KCSG Study Group: Addition of docetaxel to S-1 without platinum
prolongs survival of patients with advanced gastric cancer: A
randomized study (START). J Cancer Res Clin Oncol. 140:319–328.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kobayashi M, Sakamoto J, Namikawa T,
Okamoto K, Okabayashi T, Ichikawa K and Araki K: Pharmacokinetic
study of paclitaxel in malignant ascites from advanced gastric
cancer patients. World J Gastroenterol. 12:1412–1415. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Kitayama J, Ishigami H, Yamaguchi H,
Yamashita H, Emoto S and Kaisaki S: S-1 plus intravenous and
intraperitoneal Paclitaxel for gastric cancer with peritoneal
metastasis. Gastrointest Cancer Res. 5(Suppl 1): S10–S13.
2012.PubMed/NCBI
|
|
79
|
Toriumi F, Kubota T, Saikawa Y, Yoshida M,
Otani Y, Watanabe M, Kumai K and Kitajima M: Thymidylate synthetase
(TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as
an indicator in determining chemosensitivity to 5-fluorouracil in
advanced gastric carcinoma. Anticancer Res. 24:2455–2463.
2004.PubMed/NCBI
|
